摘要
随着结直肠癌病例发病率增高,全球每年新发病例超过100万例^[1]。目前对结直肠癌的治疗措施不断改进,除传统的手术、放疗、化疗3种主要治疗手段外,近年出现了被誉为第4种手段的分子靶向治疗,尤其是对于晚期结直肠癌总体疗效较差的情况下,
出处
《实用肿瘤杂志》
CAS
2013年第1期10-14,共5页
Journal of Practical Oncology
二级参考文献7
-
1van Cutsem E,Peeters M,Siena S,et al.Open-label,randomized,phase 3 clinical trial of Panitumumab plus best supportive care versus best supportive cave in patients with chemotherapy-refractory metastatic colorectal cancer[J].J Clin Oncol,2007,25:1658-1664.
-
2Berlin J,Posey J,Tchekmedyian S,et al.Panitumumab with Irinotecan/Leucovorin/5-Fluorouracil for first-line treatment of metastatic colorectal cancer[J].Clin Colorectal Cancer,2007,6:427-432.
-
3Amado RG,Wolf M,Peeters M,et al.Wildtype KRAS is required for Panitumumab efficacy in patients with metastatic colorectal cancer[J].J Clin Oncal,2008,26:1626-1634.
-
4Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus Irinotecan,Fluorouracil,and Leucovorin for metastatic colorectal cancer[J].N Engl J Med,2004,350:2335-2342.
-
5Giantonio BJ,Catalano PJ,Meropol NJ,et al.Bevacizumab in combination with Oxaliplatin,Fluorouracil,and Leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer:Results from the Eastern Cooperative Oncology Group Study E3200[J].J Clin Oncol,2007,25:1539-1544.
-
6Saltz LB,Lenz HJ,Kindler HL,et al.Randomized phase Ⅱ trial of Cetuximab,Bevacizumab,and Irinotecan compared with Cetuximab and Bevacizumab alone in Irinotecan-refractory colorectal cancer:The BOND-2 study[J].J Clin Oncol,2007,25:4557-4561.
-
7Tol J,Koopman M,Cats A,et al.Chemotherapy,Bevacizumab,and Cetuximab in metastatic colorectal cancer[J].N Engl J Med,2009,360:563-572.
共引文献23
-
1郑镇木,罗湛滨.结直肠癌靶向治疗研究进展[J].中华临床医师杂志(电子版),2011,5(16):4817-4820. 被引量:2
-
2徐建波,何裕隆.转移性结直肠癌的临床治疗进展[J].消化肿瘤杂志(电子版),2010,2(4):245-248. 被引量:4
-
3聂芳,沈骏,徐锡涛,朱明明,童锦禄,冉志华.表皮生长因子受体单克隆抗体在结直肠癌治疗中作用的系统评价[J].胃肠病学,2009,14(7):388-393.
-
4吴德庆,陈利生,曹云飞.单克隆抗体治疗晚期或转移性结直肠癌的进展[J].结直肠肛门外科,2009,15(4):280-284. 被引量:2
-
5徐瑞华,骆卉妍.结直肠癌靶向治疗药物研究进展[J].中国药房,2010,21(14):1254-1257. 被引量:5
-
6李宇红.大肠癌靶向药物治疗进展评述[J].医学与哲学(B),2010,31(4):10-12. 被引量:2
-
7戴广海.大肠癌常见诊疗误区解析[J].医学与哲学(B),2010,31(4):19-21. 被引量:2
-
8马冬,杨冬阳.贝伐单抗联合吉西他滨和厄洛替尼在转移性胰腺癌的Ⅲ期临床研究[J].循证医学,2010,10(3):139-142. 被引量:1
-
9陈万灵,欧阳学农.新药贝伐单抗的临床应用进展[J].中国肿瘤,2010,19(8):534-539. 被引量:18
-
10钱羽,魏少忠.结直肠癌分子靶向治疗的现状及展望[J].肿瘤防治研究,2011,38(12):1458-1461. 被引量:1
同被引文献53
-
1李凡,韩琤波,马洁韬,吴红.结直肠癌原发灶和转移灶KRAS基因状态比较的Meta分析[J].中华临床医师杂志(电子版),2011,5(13):3834-3838. 被引量:3
-
2Michael M, Zalcberg J, (,ibbs P, et al. A phase l trial of imatinib ill combination ith mFOI.FOX6-1)evacizumab in patienls ith advanced colorectal cant!er [ J ]. Cancel' Chemolher Pharmacol, 2013,71 ( 2 ) :321 - 330.
-
3Duereux M, A(lenis A, Pignon JP, et al. Effic;:wv and safely of bevaeizumal)-l)ased combination regimens in palients with previously unlrealt,l rnelastali,t: eoh)recla] cancer: final results ti'om a randomised phase II study of l)evaeizumab plus 5-fluorouraeil, letwoorin plus irinoteean ersus bevaeizumab plus capeeitabine plus irilotecan ( FNCLCC ACCOR1) 13/0503 tudv) [ J ]. EurJ Cancer, 2013,49(6) :1236 - 1245.
-
4Varol U, Oktay E, Yildi6m M, et al. Tumor chara('teristics and metastatic sites may predict bevaeizumab efficacy in the firsl-line treatnmnt of metastatic eoloreetal eancer[J]. Mol Clin ()neol, 2014,2 (1):166-170.
-
5Von Minekwilz G, Loibl S, Unteh M, et al. Survival after neoadjuvant chemotherapy with or without I)evacizmual) or everolimus tr HER2-negalive primary breast cancer ( GBG 44-GeparQuinto) dagger [J] . AnnOnc'ol, 2014,25 ( 12 ) : 2363 - 2372.
-
6Stein A, Glockzin G, Wienke A, et al. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature [J]. BMC Cancer, 2012,12:356.
-
7Loupakis F, Glockzin G, Wienke A, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer[J]. N Engl J ned, 2014,371 (17): 1609 - 1618.
-
8Tejpar S, Prenen H, Mazzone M. Overcoming resistance to antiangiogenic therapies [ J ]. Oncologist, 2012, 17 (8) :1039 - 1050.
-
9Lieu CH, Tran H, Jiang ZQ, et al. The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer [ J ]. PLoS One, 2013,8(10) :e77117.
-
10Yang F, Tang X, Riquelme E, et al. Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy [ J ]. Cancer Res, 2011,71 (16) :5512 - 5521.
引证文献6
-
1秦锐,石燕,陈丽,吴志勇,韩雅琳,戴广海.西妥昔单抗转化性治疗大肠癌肝转移患者的临床观察[J].解放军医学院学报,2014,35(7):696-700. 被引量:2
-
2马妮娜,王婧,李卉惠,张瑞雪,曹邦伟.XELOX与FOLFOX6方案一线治疗晚期结直肠癌的近期疗效及不良反应比较[J].临床和实验医学杂志,2014,13(13):1052-1055. 被引量:12
-
3刘洪金,贾森浩,张莹莹,张芦芦,付艳,张力文,吴柏寿,王晓朋,杜楠.贝伐珠单抗对结直肠癌细胞串珠素表达的影响[J].实用肿瘤杂志,2015,30(4):325-330.
-
4陈淑珍.结直肠癌靶向治疗的现状与未来[J].世界华人消化杂志,2017,25(4):307-315. 被引量:1
-
5高竹筠.生物靶向药物贝伐单抗与伊立替康用于晚期结直肠癌患者中的效果以及临床护理体会[J].海峡药学,2017,29(3):194-195. 被引量:3
-
6范晓翔,谢阳阳,沈伟男,戴晓宇.FOLFIRI联合EGFR单抗治疗不同部位Kras基因野生型结直肠癌肝转移的效果研究[J].现代实用医学,2018,30(4):471-474.
二级引证文献18
-
1葛月梅.预见性护理在贝伐单抗联合FOFIRI方案治疗晚期结直肠癌患者中的作用[J].沈阳药科大学学报,2021,38(S02):81-81. 被引量:2
-
2周毅.贝伐珠单抗在结直肠癌靶向治疗中的临床应用[J].生命科学仪器,2023,21(S02):68-68.
-
3高炳乾,李继林,赖浩,冯雁,林源.XELOX与FOLFOX6辅助化疗方案在标准周期下治疗直肠癌术后患者的临床比较[J].航空航天医学杂志,2018,29(12):1435-1438.
-
4王先坤,王雪,黄建.大蒜素对大鼠实验性大肠癌的作用及其机制研究[J].天然产物研究与开发,2016,28(6):943-948. 被引量:9
-
5朱雅婷,张倩,汤旭山,刘恒戈,柳惠斌.XELOX方案治疗晚期结直肠癌的疗效及安全性分析[J].现代医药卫生,2017,33(4):547-548. 被引量:4
-
6纪光晰,马春燕,梁志军,王宇,贾战生.FOLFOX4方案对引起乙型肝炎病毒再激活的晚期肝癌患者的疗效[J].山西医药杂志,2017,46(4):395-396. 被引量:4
-
7舒科平,刘玉君.XELOX 与 FOLFOX6化疗方案在老年结直肠癌患者中的应用价值比较[J].中国基层医药,2017,24(4):609-612. 被引量:1
-
8尹进南,徐进,岳茂兴,毛商,顾新刚.K-ras突变型晚期结直肠癌患者采用奥沙利铂或伊立替康联合氟尿嘧啶治疗的临床对比研究[J].临床和实验医学杂志,2017,16(9):901-904. 被引量:6
-
9龚庆豪,戴刚,陈海群,费哲为,蔡一亭.抗瘤增效方联合替吉奥治疗晚期结直肠癌疗效及对患者生存质量、血清肿瘤标志物的影响[J].中国实验方剂学杂志,2017,23(11):171-176. 被引量:12
-
10侯晓茹.XELOX方案与FOLFOX6方案治疗结直肠癌的疗效及安全性比较[J].齐齐哈尔医学院学报,2017,38(15):1765-1766. 被引量:1
-
1胡建昆,赵林勇,陈心足.3D腹腔镜胃癌根治术的应用及前景[J].中国普外基础与临床杂志,2016,23(8):901-904. 被引量:8
-
2袁汇,孔守芳,钟金妍.微小RNA在宫颈癌早期诊断中的应用及前景[J].中国医学工程,2014,22(3):195-196. 被引量:2
-
3冯旺琴,崔竹梅.细胞分化与子宫内膜癌[J].肿瘤学杂志,2009,15(5):455-459. 被引量:2
-
4唐金琦,谭万龙.液基细胞学在膀胱肿瘤诊断中的进展[J].现代泌尿外科杂志,2016,21(4):315-318. 被引量:2
-
5陈静平.腹腔镜技术在妇科恶性肿瘤治疗中的应用及前景[J].华夏医学,2008,21(2):381-383.
-
6韩晓凤,曹兰芳,朱菁.ALA-PDT在白血病中的研究进展[J].应用激光,2006,26(6):473-477.
-
7刘越清.周围型肺癌56例的CT征象及临床意义[J].中国药物与临床,2013,13(5):616-617. 被引量:7
-
8黄建峰,沈振亚,许林,祝晓.Survivin在非小细胞肺癌手术切缘中的表达及与其预后的关系[J].实用癌症杂志,2008,23(4):414-414. 被引量:2
-
9刘金环.乳腺癌的防与治[J].开卷有益(求医问药),1995,0(4):20-21.
-
10郭茹隹.英国的癌症发病率正日趋增加[J].国外医学情报,2004,25(5):7-7.